

## Refine Search

### Search Results -

Terms	Documents
L16 and (cytosine near10 dioxolane)	13

Database:

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

Search:

L17





### Search History

DATE: Monday, October 16, 2006   
 [Purge Queries](#)   
 [Printable Copy](#)   
 [Create Case](#)

<u>Set</u> <u>Name</u> side by side	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
<i>DB=PGPB,USPT; PLUR=YES; OP=OR</i>			
<u>L17</u>	L16 and (cytosine near10 dioxolane)	13	<u>L17</u>
<u>L16</u>	L15 and (cancer or tumor)	376	<u>L16</u>
<u>L15</u>	514/274.ccls.	959	<u>L15</u>
<u>L14</u>	L13 and cytosine	1	<u>L14</u>
<u>L13</u>	L12 and @pd<19950217	35	<u>L13</u>
<u>L12</u>	L10 and (cancer or tumor)	342	<u>L12</u>
<u>L11</u>	L10 and (cytosine near10 (dioxolane))	0	<u>L11</u>
<u>L10</u>	514/396.ccls.	903	<u>L10</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L9</u>	(dioxolane near8 cytosine) same ((treatment or prevention or therap\$5) near8 (cancer or tumor))	26	<u>L9</u>
<i>DB=PGPB,USPT; PLUR=YES; OP=OR</i>			
<u>L8</u>	L4 and cytosine	29	<u>L8</u>

<u>L7</u>	L6 and cytosine	23	<u>L7</u>
<u>L6</u>	L4 and tumor	43	<u>L6</u>
<u>L5</u>	L4 and tumore	0	<u>L5</u>
<u>L4</u>	L3 and cancer	59	<u>L4</u>
<u>L3</u>	(Yung adj Chi) near Cheng	87	<u>L3</u>
<u>L2</u>	(Chung adj K) near Chu	88	<u>L2</u>
<u>L1</u>	(Chung adj Chu) AND @pd>20060517	4	<u>L1</u>

END OF SEARCH HISTORY



Day : Monday  
Date: 10/16/2006

Time: 17:37:16

## Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.  
Additionally, enter the **first few letters** of the Inventor's First name.

**Last Name**

**First Name**

Chu

Chung

Search

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



## Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.  
Additionally, enter the **first few letters** of the Inventor's First name.

**Last Name****First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

(FILE 'HOME' ENTERED AT 17:50:10 ON 16 OCT 2006)

FILE 'REGISTRY' ENTERED AT 17:50:18 ON 16 OCT 2006

E "(-)-(2S,4S)-1-(2-HYDROXYMETHYL-1,3-DIOXOLANE-4-YL)CYTOSINE"/

E "(-)-(2S,4S)-1-(2-HYDROXYMETHYL-1,3-DIOXOLANE-4-YL)-CYTOSINE"

FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 17:51:41 ON 16 OCT 2006

L1 106 S (CYTOSINE (10A) DIOXOLANE)

L2 8 S L1 (P) ((TREAT? OR THERAP? OR PREVEN?) (10A) (CANCER? OR TUMO

L3 8 DUPLICATE REMOVE L2 (0 DUPLICATES REMOVED)

L3 ANSWER 1 OF 8 USPATFULL on STN

TI Human growth hormone antagonists

AB A method is disclosed for treating disorders in which human growth hormone is implicated by administering to a mammal an effective amount of an antagonist according to the general formula (I) ##STR1## wherein X, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined herein.

ACCESSION NUMBER: 2006:215627 USPATFULL

TITLE: Human growth hormone antagonists

INVENTOR(S): Cochran, Andrea G., San Francisco, CA, UNITED STATES

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006183784	A1	20060817
APPLICATION INFO.:	US 2006-401821	A1	20060410 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-172247, filed on 14 Jun 2002, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-298358P	20010615 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	900	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L3 ANSWER 2 OF 8 USPATFULL on STN

TI Stereoselective process for the production of dioxolane nucleoside analogues

AB The present invention relates to a process for producing a compound of formula (I); said process comprising the steps of: a) subjecting a compound of formula (II) to an enzymatic diastereomeric resolution in the presence of a suitable amount of enzyme chosen from Pig Liver Esterase or Porcine Pancreatic Lipase b) recovering said compound of formula (I). The invention also provides a process for producing a compound of formula (III); said process comprising the steps of: a) subjecting a compounds of formula (IV) to an enzymatic diastereomeric resolution in the presence of a suitable amount of enzyme chosen from Candida Antarctica "A" lipase, Candida Antarctica "B" lipase, Candida Lypolitica Lipase or Rhizomucor Miehei Lipase b) recovering said compound of formula (III). ##STR1##

ACCESSION NUMBER: 2006:159230 USPATFULL

TITLE: Stereoselective process for the production of dioxolane nucleoside analogues

INVENTOR(S): Cimpoia, Alex, Verdun, CANADA

Lalonde, James Joseph, Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006134763	A1	20060622
APPLICATION INFO.:	US 2003-535235	A1	20031118 (10)
	WO 2003-CA1798		20031118
			20051219 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-426821P	20021118 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON  
BLVD., SUITE 1400, ARLINGTON, VA, 22201, US  
NUMBER OF CLAIMS: 24  
EXEMPLARY CLAIM: 1  
LINE COUNT: 677  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 8 USPATFULL on STN

TI CDR-repaired antibodies

AB The present application concerns restoring antigen binding during  
humanization of antibodies through the selection of repaired  
hypervariable regions rather than through framework changes.

ACCESSION NUMBER: 2006:144857 USPATFULL

TITLE: CDR-repaired antibodies

INVENTOR(S): Dennis, Mark S., San Carlos, CA, UNITED STATES

PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006122377	A1	20060608
APPLICATION INFO.:	US 2005-61841	A1	20050218 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-545840P	20040219 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	5212	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 8 USPATFULL on STN

TI Antibody formulations

AB The present application describes antibody formulations, including  
monoclonal antibodies formulated in histidine-acetate buffer, as well as  
a formulation comprising an antibody that binds to domain II of HER2  
(for example, Pertuzumab), and a formulation comprising an antibody that  
binds to DR5 (for example, Apomab).

ACCESSION NUMBER: 2006:104421 USPATFULL

TITLE: Antibody formulations

INVENTOR(S): Andya, James, Millbrae, CA, UNITED STATES  
Gwee, Shiang C., Pacifica, CA, UNITED STATES  
Liu, Jun, Pacifica, CA, UNITED STATES  
Shen, Ye, San Francisco, CA, UNITED STATES

PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006088523	A1	20060427
APPLICATION INFO.:	US 2005-254182	A1	20051019 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-620413P	20041020 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US	

NUMBER OF CLAIMS: 79  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 34 Drawing Page(s)  
LINE COUNT: 6519  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 8 USPATFULL on STN

TI HER2 antibody composition

AB A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.

ACCESSION NUMBER: 2006:21067 USPATFULL

TITLE: HER2 antibody composition

INVENTOR(S): Kao, Yung-Hsiang, San Mateo, CA, UNITED STATES  
Vanderlaan, Martin, San Francisco, CA, UNITED STATES

PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006018899	A1	20060126
APPLICATION INFO.:	US 2005-182908	A1	20050715 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-590202P	20040722 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Page(s)	
LINE COUNT:	4053	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 8 USPATFULL on STN

TI Process for producing dioxolane nucleoside analogues

AB The present invention relates to a process conducted in a single reaction vessel for producing a dioxolane nucleoside analogue of formula I or a pharmaceutically acceptable salt thereof; the process comprising the steps of adding a Lewis acid, a silylating agent and a non-silylated purine or pyrimidine base or an analogue thereof to a dioxolane of formula II. The invention also provides a process for producing a dioxolane compound of formula III; by reacting a dioxolane compound of formula IV in a suitable solvent in the presence of DIB and I.sub.2, using a suitable source of energy.

ACCESSION NUMBER: 2005:99719 USPATFULL

TITLE: Process for producing dioxolane nucleoside analogues

INVENTOR(S): Bydlinski, Gregory, Montreal, CANADA  
Yu, Qing, Laval, CANADA  
Cimpoia, Alex, Verdun, CANADA

PATENT ASSIGNEE(S): SHIRE BIOCHEM INC, Quebec, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005085638	A1	20050421
APPLICATION INFO.:	US 2003-502440	A1	20030123 (10)
	WO 2003-CA85		20030123

NUMBER	DATE
--------	------



PRIORITY INFORMATION: US 2002-350968P 20020125 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON  
BLVD., SUITE 1400, ARLINGTON, VA, 22201, US  
NUMBER OF CLAIMS: 73  
EXEMPLARY CLAIM: 1  
LINE COUNT: 918  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 8 USPATFULL on STN

TI Human growth hormone antagonists

AB A method is disclosed for treating disorders in which human growth  
hormone is implicated by administering to a mammal an effective amount  
of an antagonist according to the general formula (I) ##STR1##

wherein X, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined  
herein.

ACCESSION NUMBER: 2003:141010 USPATFULL  
TITLE: Human growth hormone antagonists  
INVENTOR(S): Cochran, Andrea G., San Francisco, CA, UNITED STATES  
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003096852	A1	20030522
APPLICATION INFO.:	US 2002-172247	A1	20020614 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-298358P	20010615 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	909	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 8 USPATFULL on STN

TI Compounds and methods for the treatment of cancer

AB (-)-(2S,4S)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred  
to as (-)-OddC) and its use to treat cancer in animals, including  
humans.

ACCESSION NUMBER: 1998:122418 USPATFULL  
TITLE: Compounds and methods for the treatment of cancer  
INVENTOR(S): Chu, Chung K., Athens, GA, United States  
Cheng, Yung-Chi, Woodbridge, CT, United States  
PATENT ASSIGNEE(S): University of Georgia Research Foudation, Athens, GA,  
United States (U.S. corporation)  
Yale University, New Haven, CT, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5817667		19981006
APPLICATION INFO.:	US 1994-301298		19940906 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-937845, filed on 19 Oct 1992		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Goldberg, Jerome D.		
LEGAL REPRESENTATIVE:	Coleman and Sudol		

NUMBER OF CLAIMS: 19  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)  
LINE COUNT: 1051  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.